Latham & Watkins Advises Underwriters in Intellia Therapeutics’ Public Offering of Common Stock

Intellia Therapeutics, Inc., a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, has announced the pricing of an underwritten public offering of 4,794,521 shares of its common stock at a public offering price of US$36.50 per share. Intellia also granted the underwriters a 30-day option to purchase up to an additional 719,178 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be US$175 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Intellia. Goldman Sachs & Co. LLC, Jefferies and SVB Leerink are acting as joint book-running managers for the offering. The offering is expected to close on or about December 4, 2020, subject to customary closing conditions.

Latham & Watkins LLP represented the underwriters in the offering with a capital markets deal team led by Boston partner Peter Handrinos and New York partner Nathan Ajiashvili, with New York associates Sandy Kugbei and Darby Dietrich.